Membranous nephropathy (MN) is a glomerular disease that can occur at all ages. In adults,
it is the most frequent cause of nephrotic syndrome. In~ 80% of patients, there is no …

Idiopathic membranous nephropathy (INM) remains a common cause of the nephrotic
syndrome in adults. The autoimmune nature of IMN was clearly delineated in 2009 with the …

Glomerular disease, be it primary or secondary, occurring in the setting of systemic
autoimmune diseases, infections, drugs, or malignancy, affects individuals of all ages. In …

Background A cyclic corticosteroid-cyclophosphamide regimen is the first-line therapy for
membranous nephropathy. Compared with this regimen, rituximab therapy might have a …

A cyclical corticosteroid-cyclophosphamide regimen is recommended for patients with
primary membranous nephropathy at high risk of progression. We hypothesized that …

Selective depletion of B cells with the mAb rituximab may benefit the autoimmune
glomerular disease idiopathic membranous nephropathy (IMN). Here, we describe our …

The nephrotic syndrome is defined by a urinary protein level exceeding 3.5 g per 1.73 m2 of
body-surface area per day. At the turn of the century, clinicians distinguished a nephritic …

The KDIGO guideline for glomerulonephritis is designed to assist health-care providers in
treating patients with glomerular diseases. A guideline is not a set of rules but is intended to …

Background and objectives: It was postulated that in patients with membranous nephropathy
(MN), four weekly doses of Rituximab (RTX) would result in more effective B cell depletion, a …

Cyclosporine in patients with steroid-resistant membranous nephropathy: A randomized
trial. Background A clinical trial of cyclosporine in patients with steroid-resistant …